dusquetide

Soligenix's dusquetide (SGX945) receives EU orphan drug designation for Behçet's Disease, backed by Phase 2a data showing 40% ulcer reduction with no adverse events.

Soligenix's SGX945 earns UK Promising Innovative Medicine designation for Behçet's Disease, enabling early patient access with Phase 2 data showing 40% ulcer improvement.

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.